Clinical Trials Browser

NCT00070499 2026-03-18

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Phase 2 Active not recruiting

406 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00028002 2020-10-26

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Phase 2 Completed

63 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 2 Completed

26 enrolled 11 charts

GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00068380 2018-07-11

A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Phase 2 Completed

17 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT00079313 2017-07-02

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Phase 2 Completed

7 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic

NCT00045734 2017-05-15

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Phase 2 Completed

23 enrolled 9 charts

CNS

Brain Neoplasms, Meningioma

NCT00039585 2015-04-30

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Phase 2 Completed

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00030667 2015-04-15

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Phase 2 Completed

100 enrolled

CNSGastrointestinalSarcoma

Neuroblastoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

NCT00470470 2014-12-23

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

30 enrolled 7 charts

Dermatologic

Melanoma

NCT00087152 2014-06-09

S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

Phase 2 Completed

27 enrolled 9 charts

Breast

Breast Neoplasms

NCT00039416 2014-02-25

Imatinib Mesylate in Treating Patients With Myelofibrosis

Phase 2 Completed

18 enrolled

MyeloidOther hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT01005758 2014-01-10

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2 Unknown

180 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00052949 2013-10-08

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Completed

91 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

Phase 2 Unknown

76 enrolled

CNS

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

NCT00031915 2013-06-19

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Phase 2 Completed

Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT00091078 2013-06-05

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Phase 2 Terminated

96 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00049192 2013-06-04

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 2 Completed

43 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00618501 2013-03-26

Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2 Completed

50 enrolled

Other hematologic neoplasm

Leukemia

NCT00068783 2013-02-28

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 2 Completed

40 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT00084630 2013-02-28

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Phase 2 Completed

40 enrolled

Sarcoma

Fibrosarcoma, Sarcoma, Dermatofibrosarcoma

NCT00025246 2013-02-20

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Phase 2 Completed

89 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00041041 2013-02-20

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Completed

60 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT00041340 2013-01-23

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Phase 2 Completed

37 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00045188 2013-01-23

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

35 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00054431 2013-01-23

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Phase 2 Completed

80 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase

NCT00030394 2013-01-17

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 2 Completed

64 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00042952 2013-01-17

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Phase 2 Terminated

32 enrolled

Genitourinary

Dysgerminoma, Testicular Neoplasms, Seminoma

NCT00112775 2011-06-07

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase